- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Pleural disorders.
Displaying page 1 of 2.
| EudraCT Number: 2012-000599-40 | Sponsor Protocol Number: | Start Date*: 2012-06-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:North Bristol NHS Trust | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Malignant pleural effusions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002484-60 | Sponsor Protocol Number: 2020-002484-6060 | Start Date*: 2021-07-12 | |||||||||||||||||||||
| Sponsor Name:Odense Universityhospital | |||||||||||||||||||||||
| Full Title: Intrapleural Fibrinolysis and DNase versus VATS for the treatment of pleural empyema: a randomized, controlled trial. | |||||||||||||||||||||||
| Medical condition: Pleural Empyema | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-004374-25 | Sponsor Protocol Number: 61528 | Start Date*: 2020-03-25 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
| Full Title: Thoracic duct identification with Indocyanine green fluorescence during minimally invasive esophagectomy with patient in prone position | |||||||||||||
| Medical condition: Chylothorax is a serioso post-operative complication, which occurs in 2-12% of patients undergoing esophagectomy. Thoracic duct lesion leads to a reduction of body fluids and albumin resulting in h... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003974-33 | Sponsor Protocol Number: CE150171 | Start Date*: 2021-05-25 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
| Full Title: Thoracic duct identification with indocyanine green fluorescence during esophagectomy | |||||||||||||
| Medical condition: Chylothorax is a serious post-operative complication, with occurs in 2-12% of patients undergoing esophagectomy. Thoracic duct lesion leads to a reduction of body fluids and albumin resulting in hy... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002184-26 | Sponsor Protocol Number: 2012/176/HP | Start Date*: 2014-01-20 | |||||||||||
| Sponsor Name:CHU de Rouen | |||||||||||||
| Full Title: Efficacy of parietal continous infiltration of local anesthesic on diaphragmatic function after upper abdominal surgery through a subcostal incision | |||||||||||||
| Medical condition: Diaphragmatic function after upper abdominal surgery through a subcostal incision | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011008-43 | Sponsor Protocol Number: CRAD001AIT16 - EVERHEART | Start Date*: 2009-06-24 | |||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||
| Full Title: Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study) | |||||||||||||
| Medical condition: de novo heart transplant patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-003059-36 | Sponsor Protocol Number: Bay 58-2667/12480 | Start Date*: 2007-12-10 | |||||||||||
| Sponsor Name:Bayer Healthcare AG | |||||||||||||
| Full Title: Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with acute deco... | |||||||||||||
| Medical condition: Patients with acute decompensated chronic congested heart failure | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003931-12 | Sponsor Protocol Number: BXU513667 | Start Date*: 2017-12-13 | |||||||||||
| Sponsor Name:Baxter Healthcare Corporation | |||||||||||||
| Full Title: A Randomized Controlled Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection. | |||||||||||||
| Medical condition: Postoperative air leakage. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002416-27 | Sponsor Protocol Number: INFECIR2 | Start Date*: 2013-10-23 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Fundacio Clinic per a la recerca biomedica | ||||||||||||||||||||||||||||||||||||||
| Full Title: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mo... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with advanced cirrhosis (serum creatinine > 1.2 mg/dl, serum sodium < 130 mEq/l and/or serum bilirubin > 4 mg/dl), signs of systemic inflammation and urinary infection, pneumonia, skin/sof... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: NO (Completed) ES (Prematurely Ended) IT (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-003157-27 | Sponsor Protocol Number: Sobi.PEGCET-201 | Start Date*: 2021-12-17 | |||||||||||
| Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL) | |||||||||||||
| Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (... | |||||||||||||
| Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005604-35 | Sponsor Protocol Number: APEC1621B | Start Date*: 2022-01-18 | |||||||||||
| Sponsor Name:National Cancer Institute (NCI) | |||||||||||||
| Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations | |||||||||||||
| Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
| Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
| Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-002727-38 | Sponsor Protocol Number: OMS721-HCT-002 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
| Sponsor Name:Omeros Corporation | |||||||||||||||||||||||
| Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant... | |||||||||||||||||||||||
| Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Completed) NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2016-004271-52 | Sponsor Protocol Number: IGMFGG-2016 | Start Date*: 2018-05-11 | |||||||||||
| Sponsor Name:Francisco de la Gala/ Ignacio Garutti | |||||||||||||
| Full Title: IMPACTO DE LA ADMINISTRACIÓN DE LIDOCAINA INTRAVENOSA O PARAVERTEBRAL EN PERFUSIÓN CONTINUA DURANTE EL INTRAOPERATORIO DE LA CIRUGÍA DE RESECCIÓN PULMONAR SOBRE LA APARICIÓN DE COMPLICACIONES POS... | |||||||||||||
| Medical condition: patients undergoing Lung resection surgery | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003470-47 | Sponsor Protocol Number: 74730.041.20 | Start Date*: 2020-08-27 | |||||||||||
| Sponsor Name:UMCU Utrecht [...] | |||||||||||||
| Full Title: BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY – AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL | |||||||||||||
| Medical condition: Protection Covid infection by patients with chronic diseases or major surgery | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004939-24 | Sponsor Protocol Number: BPF-001 | Start Date*: 2020-06-02 | |||||||||||
| Sponsor Name:Cell and Gene Therapy Catapult | |||||||||||||
| Full Title: Phase I/II open-label study to assess the safety, tolerability and efficacy of a novel tissue engineered airway product, consisting of expanded autologous bone marrow (BM) derived Mesenchymal Strom... | |||||||||||||
| Medical condition: Bronchopleural fistula (BPF) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002517-11 | Sponsor Protocol Number: CD0001 | Start Date*: 2012-02-22 | ||||||||||||||||
| Sponsor Name:UCB BIOSCIENCES GmbH | ||||||||||||||||||
| Full Title: A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with mod... | ||||||||||||||||||
| Medical condition: Moderate to severe Crohn’s disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-006812-10 | Sponsor Protocol Number: BBI-20201001 | Start Date*: 2023-04-05 | ||||||||||||||||
| Sponsor Name:Bolt Biotherapeutics, Inc. | ||||||||||||||||||
| Full Title: Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors. | ||||||||||||||||||
| Medical condition: Advanced HER2-Expressing Solid Tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-011740-19 | Sponsor Protocol Number: GS-US-205-0127 | Start Date*: 2015-02-02 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) a... | |||||||||||||
| Medical condition: Cystic Fibrosis subjects with chronic Burkholderia spp. infection of the airways. | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000398-11 | Sponsor Protocol Number: GS-US-205-0170 | Start Date*: 2015-02-03 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for t... | |||||||||||||
| Medical condition: Cystic fibrosis and chronic infection of lower respiratory tract with Pseudomonas aeruginosa | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.